Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

3.0K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
3.0K
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

1.1K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.1K
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

9.4K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
9.4K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

3.6K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
3.6K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

2.4K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.4K
Principles of Drug Action01:24

Principles of Drug Action

6.9K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
6.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.

Blood·2017
See all related articles

Related Experiment Video

Updated: Sep 27, 2025

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
09:39

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1

Published on: February 13, 2018

9.7K

STING Agonists/Antagonists: Their Potential as Therapeutics and Future Developments.

Danilo Guerini1

  • 1Novartis NIBR ATI, 4056 Basel, Switzerland.

Cells
|April 12, 2022
PubMed
Summary
This summary is machine-generated.

The cyclic GMP-AMP synthase (cGAS) STING pathway is crucial for innate immunity and implicated in autoinflammatory disorders. Developing specific modulators for clinical use remains challenging but shows promise for future therapies.

Keywords:
STINGcGASdrug discovery

More Related Videos

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
07:09

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

48.5K
Intracranial Pharmacotherapy and Pain Assays in Rodents
02:26

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

5.4K

Related Experiment Videos

Last Updated: Sep 27, 2025

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
09:39

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1

Published on: February 13, 2018

9.7K
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
07:09

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

48.5K
Intracranial Pharmacotherapy and Pain Assays in Rodents
02:26

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

5.4K

Area of Science:

  • Immunology
  • Molecular Biology
  • Genetics

Background:

  • The cGAS STING pathway is a key component of the innate immune response.
  • Dysregulation of this pathway is linked to type I interferonopathies and other diseases like cardiac failure.
  • Genetic mutations activating STING or affecting cGAS drive rare autoinflammatory conditions.

Purpose of the Study:

  • To review potential therapeutic indications for modulating the cGAS STING pathway.
  • To provide an overview of efforts in developing STING modulators (agonists and antagonists) for clinical research.
  • To discuss the potential of these modulators as therapeutic drugs.

Main Methods:

  • Literature review of preclinical and clinical data on the cGAS STING pathway.
  • Analysis of current challenges and progress in developing small molecule STING modulators.
  • Exploration of potential clinical applications and therapeutic strategies.

Main Results:

  • While STING agonists have entered oncology trials, progress is slow, and developing selective antagonists is difficult.
  • Novel low molecular weight compounds with potential therapeutic applications are emerging.
  • No clinical data currently demonstrates therapeutic benefit from modulating the cGAS STING pathway.

Conclusions:

  • Modulating the cGAS STING pathway holds therapeutic potential for various diseases beyond classical immune disorders.
  • The development of clinically viable STING modulators is ongoing, with new compounds showing promise.
  • Further research and clinical trials are needed to validate the therapeutic efficacy of cGAS STING pathway modulators.